43 completed. 43 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 43 | Completed 43 |
| Phase 2 | 2 | Completed 2 |
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo - Anemia, Iron Deficiency, Hyperphosphatemia | Phase 3 | Completed | USRC Kidney Research | 289 | 2022-03-30 | 2025-08-29 |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791 - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 213 | 2021-03-15 | 2023-08-02 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 169 | 2021-03-15 | 2021-10-28 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 165 | 2021-03-08 | 2021-09-08 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis KHK7791 - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 54 | 2021-03-03 | 2022-01-11 |
| Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients Phosphate-binder intervention, Phosphorus-restricted dietary intervention - Maintenance Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Chen Jing | 123 | 2019-11-29 | 2021-08-31 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric Citrate, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Panion & BF Biotech Inc. | 240 | 2019-06-19 | 2021-03-10 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric citrate tablet, Sevelamer carbonate tablet - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Sinomune Pharmaceutical Co., Ltd | 239 | 2019-05-24 | 2024-04-17 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| PA21 Safety and Efficacy in Adult Chinese Subjects PA21, sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 286 | 2018-08-31 | 2021-06-02 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Tenapanor, Placebo, Sevelamer Carbonate - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 1559 | 2018-01-08 | 2023-06-29 |
| Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China Placebo, Sevelamer Carbonate (GZ419831) - Hyperphosphatemia | Phase 3 | Completed | Sanofi | 202 | 2017-06-07 | 2022-03-25 |
| An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Tenapanor, Placebo - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 219 | 2016-01-01 | 2020-08-10 |
| Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Ferric Citrate - Chronic Kidney Disease, Hyperphosphatemia | Phase 3 | Completed | Denver Nephrologists, P.C. | 200 | 2015-03-01 | 2018-08-01 |
| Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Osvaren Granules, Osvaren film-coated tablets - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Fresenius Medical Care Deutschland GmbH | 61 | 2014-01-01 | 2015-06-10 |
| A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia PA21 - Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 35 | 2013-04-29 | 2018-10-09 |
| A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia PA21, Sevelamer hydrochloride - Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 213 | 2013-04-23 | 2018-10-09 |
| A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia PA21 - Hemodialysis Patients With Hyperphosphatemia | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 161 | 2013-03-18 | 2018-10-09 |
| Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis ASP1585 - Chronic Kidney Disease, Renal Insufficiency | Phase 3 | Completed | Astellas Pharma Inc | 105 | 2013-03-01 | 2015-06-09 |
Showing 20 of 43. Sign in to see all of them.
Renal Insufficiency, Chronic (21) · Renal Insufficiency (11) · Kidney Failure, Chronic (9) · Kidney Diseases (3) · Anemia, Iron-Deficiency (2) · Phosphorus Metabolism Disorders (2) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Disease Progression (1) · Dyslipidemias (1) · Urologic Diseases (1) · Vascular Calcification (1)
Metabolic Diseases (43) · Nutritional and Metabolic Diseases (43) · Phosphorus Metabolism Disorders (41) · Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Male Urogenital Diseases (28) · Urogenital Diseases (28) · Chronic Disease (27) · Disease Attributes (27) · Pathologic Processes (27) · Pathological Conditions, Signs and Symptoms (27) · Urologic Diseases (27) · Kidney Diseases (25) · Renal Insufficiency (16) · Renal Insufficiency, Chronic (5)
Sevelamer (14) · ferric citrate (9) · cholebine (5) · lanthanum carbonate (5) · Calcium Carbonate (3) · calcium acetate (3) · tenapanor (3) · bixalomer (2) · sucroferric oxyhydroxide (2)
Astellas Pharma Inc (5) · Tanabe Pharma Corporation (5) · Bayer (4) · Kissei Pharmaceutical Co., Ltd. (4) · Kyowa Kirin Co., Ltd. (4) · Ardelyx (3) · Keryx Biopharmaceuticals (3) · Genzyme, a Sanofi Company (2) · Panion & BF Biotech Inc. (2) · Alebund Pharmaceuticals (1) · Chen Jing (1) · Denver Nephrologists, P.C. (1) · Fresenius Medical Care Deutschland GmbH (1) · Nabi Biopharmaceuticals (1) · Novartis (1)
Japan (18) · United States (12) · China (6) · Germany (4) · Italy (4) · Puerto Rico (4) · France (3) · Hungary (3) · Poland (3) · United Kingdom (3) · Australia (2) · Austria (2) · Czechia (2) · Malaysia (2) · North Macedonia (2)
Julia B Lewis, MD (3) · David P Rosenbaum, PhD (2) · David P Rosenbaum, Ph.D. (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Hou Fanfan, MD (1) · Samuel Blumenthal, MD (1)
PMID 40576086, PMID 38323855, PMID 42664364, PMID 37853560, PMID 21324193, PMID 23369827, PMID 23670305, PMID 24840781, PMID 25079863, PMID 26184491, PMID 26239948, PMID 26670307, PMID 33766811, PMID 34003226, PMID 35372979, PMID 37473746, PMID 37910313, PMID 37925471, PMID 42387036
2008 (1)